BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Ariana Pharma Enters Viral Hepatitis Partnership with Bio-Rad Laboratories, Inc. (BIO), INSERM and Beaujon Hospital


11/22/2010 2:49:48 PM

Paris, France, November 22, 2010 – Ariana(R) Pharma, a leader in decision support tools and services to accelerate the development and optimal use of drugs and biomarker discovery, announces today that it has entered into a partnership to improve the diagnosis and prognosis of chronic hepatitis.

Ariana is collaborating with AP-HP (Beaujon Hospital) and INSERM joined center of excellence for viral hepatitis and Bio-Rad France to apply its novel technology to the discovery of new biomarkers. The Hepachronix project pools their collective expertise to identify, develop and market new tools for the early diagnosis of fibrosis and for the prognosis of resistance to treatment. Diagnostics specialist Bio-Rad leads this 3-year-project.

This project aims to deepen understanding of the processes by which liver fibrosis (in HCV patients) evolves from an early, mild stage to serious liver diseases such as cirrhosis and hepatoma carcinoma. Detecting patients at the early stages of fibrosis is critical to treat them as early as possible. However, a rough 40 per cent of HCV infected patients do not respond to standard antiviral treatment. Hence the Hepachronix project aims to develop additional biomarkers to characterize patients responder status, and to adapt the therapy.

“Ariana(R) Pharma is looking forward to applying its expertise and KEM(R) technology to the diagnosis and prognosis of hepatitis which chronically affects many hundred million patients worldwide.” said Mohammad Afshar, CEO of Ariana(R) Pharma. “The identification and validation of new sets of biomarkers have the potential to improve diagnosis and treatment of these major public health problems.”

Ariana(R) Pharma and its partners have received funding from the French FUI and from the Ile de France region and will share the royalties from sales of the envisioned in vitro diagnostic reagents that will be marketed by Bio-Rad Laboratories. The announcement reflects Ariana(R) Pharma’s leading position in identifying biomarkers and demonstrates the strength of its KEM(R) (Knowledge Extraction and Management) platform for disease diagnosis.

Taking part in the Hepacronix project also further demonstrates Ariana's commitment to the field of biomarker identification and validation. This follows the recent announcement of the adoption of its KEM(R) technology by the FDA.

KEM(R) will be used to complement traditional statistical tools to identify signature probes and has the ability to combine genomic and proteomic data with patient characteristics to maximize the probability of an effective test. The KEM(R) system is able to generate, assess and prioritize hypotheses, handle missing data and optimize multiple objectives enhancing conventional methods of analysis.

About Ariana(R) Pharma http://www.arianapharma.com Ariana(R) Pharma delivers pioneering multi objectives decision support tools to dramatically accelerate and improve the discovery, development and safety of pharmaceutical products. Its KEM(R) knowledge extraction and management platform comprehensively mines data, including data other systems neglect, and helps scientists take simultaneous decisions involving multiple criteria and objectives. The company has established a rapidly growing software business through collaboration and licensing agreements with some of the largest pharmaceutical and biotechnology companies. Ariana(R) was founded in 2003 and is headquartered in Paris, France.

Lynne Chapman ANDREW LLOYD & ASSOCIATES http://www.ala.com lynne@ala.com

Brighton Business Centre 95 Ditchling Road Brighton BN1 4ST ENGLAND Tel: +44 1273 675100 Fax: +44 1273 675400

55 rue Boissonade 75014 Paris FRANCE Tel: +33 1 56 54 07 00 Fax: +33 1 56 54 07 01

INTERNATIONAL TECHNOLOGY MARKETS, STRATEGY & COMMUNICATION



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES